Peyronie’s agent meets phase III study endpointsDecember 2nd 2013
Data from phase III studies of collagenase clostridium histolyticum (CCH [XIAFLEX]) showed that the agent met primary endpoints related to Peyronie’s disease (PD) curvature and symptoms, and that it is effective and safe in certain subgroups of men with PD, according to Auxilium Pharmaceuticals, Inc.
New Urology Products and Services November 2013October 29th 2013
The latest products and services from SuperSonic Imagine, Auxilium Pharmaceuticals, VIVUS, the Centers for Medicare & Medicaid Services, Innovus Pharmaceuticals, Buffalo Filter, KRS Global Biotechnology, Demos Health, and Ethicon Endo-Surgery.
Testosterone doesn’t worsen lower urinary tract symptoms in men with BPHSeptember 1st 2013
A new study has found that testosterone replacement doesn’t worsen lower urinary tract symptoms related to an enlarged prostate. In fact, many men saw their symptoms improve, apparently with little effect on their prostate gland.
Agent shows benefit in PDE-5 incomplete respondersJuly 23rd 2013
A greater percentage of men who had an incomplete response to as-needed phosphodiesterase type-5 inhibitor treatment returned to normal erectile function when given tadalafil (Cialis) once daily, compared to placebo, researchers reported.
IPP placement post-T-shunt surgery appears efficaciousMarch 6th 2013
Placement of an inflatable penile prosthesis (IPP) approximately 3 months after T-shunt surgery in men with acute ischemic priapism and refractory erectile dysfunction is associated with favorable outcomes at 1 year, according to data from a small series of such patients.
PDE-5 inhibitor may improve ejaculatory functionFebruary 11th 2013
New data suggest the phosphodiesterase type-5 inhibitor tadalafil (Cialis) may be beneficial in helping men who have problems with ejaculation and orgasm, report researchers from New York-Presbyterian Hospital/Weill Cornell Medical Center, New York.
Testosterone replacement therapy displays long-term safety, efficacy in post-radical prostatectomy menFebruary 2nd 2013
Results of a single-institution study support the long-term safety and efficacy of testosterone replacement therapy for treating hypogonadism in men who have undergone radical prostatectomy.